Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient. Vinaixa Aranzazu A, Morillas-Lahuerta V, Blanco De Tord M, Carrascosa Carrillo JM, et al. Eur J Dermatol 2021 Aug 26. pii: ejd.2021.4087. doi: 10.1684/ejd.2021.4087.

Read + Share

Amedeo Smart

Independent Medical Education

Vinaixa Aranzazu A, Morillas-Lahuerta V, Blanco De Tord M, Carrascosa Carrillo JM, et al. Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient. Eur J Dermatol 2021 Aug 26. pii: ejd.2021.4087. doi: 10.1684/ejd.2021.4087.
PMID: 34463279